

Barcelona, 25th June 2020

## **OTHER RELEVANT INFORMATION**

### **Almirall S.A. divests Ansiolin® to Neuraxpharm in Italy**

Almirall, S.A. (ALM.MC), pursuant to the provisions of the Stock Exchange Act, hereby communicates the following information:

Almirall S.A. divests Ansiolin® (diazepam) to Neuraxpharm in Italy. The agreement between Neuraxpharm Italy and Almirall includes Ansiolin®'s two marketed presentations: Ansiolin® 5 mg film-coated tablets and Ansiolin® 5 mg/ml oral drops solution, in Italy.

Ansiolin® (diazepam) is a benzodiazepine indicated to treat anxiety and other somatic or psychiatric conditions associated to anxiety syndrome, while it is also indicated for insomnia.

Sincerely,

Pablo Divasson del Fraile  
Investor Relations Department  
[investors@almirall.com](mailto:investors@almirall.com)